glp journey retatrutide Research Guide: What the Phase 2 Trial Data Reported (2026) Is retatrutide better than tirzepatide?

Gentle pressure is fine, but rubbing can worsen inflammation

Following FDA review and potential European Medicines Agency approval, new pills could be available by late 2025 or 2026

The authors thank Novo Nordisk for provision of semaglutide for the study

Divis has invested roughly 650700 crore (~$80M) in capacity to manufacture peptide fragments and complex intermediates for GLP1-class molecules, including injectable tirzepatide and oral GLP1 candidates like orforglipron

Another key point: stopping therapy leads to regain in most people, which argues for getting to and staying at an effective maintenance dose rather than hovering at subtherapeutic levels

Further study confirmed the findings and showed the effects were superior compared to GLP-1 receptor agonist [42]